Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Cash & Equivalents (2017 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Cash & Equivalents for 7 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 217.36% year-over-year to $3.6 million, compared with a TTM value of $3.6 million through Dec 2025, up 217.36%, and an annual FY2025 reading of $6.6 million, up 350.01% over the prior year.
  • Cash & Equivalents was $3.6 million for Q4 2025 at Neuroone Medical Technologies, down from $6.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $16.2 million in Q4 2021 and bottomed at $1.1 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $6.0 million, with a median of $5.0 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents plummeted 72.57% in 2024, then skyrocketed 393.83% in 2025.
  • Year by year, Cash & Equivalents stood at $16.2 million in 2021, then crashed by 71.16% to $4.7 million in 2022, then tumbled by 42.56% to $2.7 million in 2023, then plummeted by 57.69% to $1.1 million in 2024, then surged by 217.36% to $3.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for NMTC at $3.6 million in Q4 2025, $6.6 million in Q3 2025, and $8.0 million in Q2 2025.